Compare ACAD & DORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | DORM |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.0B |
| IPO Year | 2000 | 1996 |
| Metric | ACAD | DORM |
|---|---|---|
| Price | $21.95 | $110.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 8 |
| Target Price | $30.55 | ★ $160.25 |
| AVG Volume (30 Days) | ★ 1.5M | 194.6K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.12 | 8.14 |
| EPS | 2.30 | ★ 6.64 |
| Revenue | $726,437,000.00 | ★ $2,130,319,000.00 |
| Revenue This Year | $18.80 | $9.70 |
| Revenue Next Year | $11.70 | $4.92 |
| P/E Ratio | ★ $9.46 | $16.61 |
| Revenue Growth | ★ 40.45 | 6.03 |
| 52 Week Low | $14.18 | $98.45 |
| 52 Week High | $28.35 | $166.88 |
| Indicator | ACAD | DORM |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 53.78 |
| Support Level | $20.81 | $109.98 |
| Resistance Level | $22.03 | $129.67 |
| Average True Range (ATR) | 0.62 | 3.18 |
| MACD | 0.06 | 1.00 |
| Stochastic Oscillator | 52.63 | 80.69 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.